Medications

What Is Wegovy? The Complete Guide to Semaglutide for Weight Loss

GLP-1 Companion · 8 min read

Wegovy has redefined what is possible with prescription weight loss treatment. As the first GLP-1 receptor agonist specifically approved for chronic weight management and later for cardiovascular risk reduction, it represents a new era in obesity medicine. This guide covers what Wegovy is, how it works, what results to expect, and whether it might be right for you.

What Is Wegovy?

Wegovy is the brand name for semaglutide 2.4 mg, a once-weekly injectable GLP-1 receptor agonist manufactured by Novo Nordisk. It was FDA-approved in June 2021 for chronic weight management in adults with obesity (BMI of 30 or greater) or those who are overweight (BMI of 27 or greater) with at least one weight-related comorbidity, such as hypertension, type 2 diabetes, or high cholesterol. In December 2022, the FDA also approved Wegovy for adolescents aged 12 and older.

In March 2024, Wegovy received an additional FDA approval to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease who also have obesity or are overweight. This made Wegovy the first anti-obesity medication to carry a cardiovascular risk reduction indication.

How Wegovy Differs from Ozempic

Wegovy and Ozempic both contain semaglutide and are made by Novo Nordisk, but they are approved for different conditions and have different dosing profiles.

• Indication: Wegovy is approved for weight management and cardiovascular risk reduction in obesity. Ozempic is approved for type 2 diabetes.
• Maximum dose: Wegovy reaches 2.4 mg per week. Ozempic maxes out at 2.0 mg per week.
• Escalation period: Wegovy uses a 16-week gradual dose escalation. Ozempic escalates more quickly.
• Target population: Wegovy is for adults (and adolescents 12+) with obesity or overweight with comorbidities. Ozempic is for adults with type 2 diabetes.
• Insurance category: Wegovy is classified as an anti-obesity medication. Ozempic is classified as a diabetes drug, which often has better insurance coverage.

Wegovy Dosing Schedule

Wegovy uses a gradual 16-week dose escalation designed to improve tolerability by allowing the body to adjust before reaching the full maintenance dose.

1. Weeks 1-4: 0.25 mg once weekly
2. Weeks 5-8: 0.5 mg once weekly
3. Weeks 9-12: 1.0 mg once weekly
4. Weeks 13-16: 1.7 mg once weekly
5. Week 17 onward: 2.4 mg once weekly (maintenance dose)

Each dose level has its own dedicated pen. Wegovy should be injected subcutaneously in the abdomen, thigh, or upper arm on the same day each week. It can be taken at any time of day, with or without food. If you cannot tolerate the 2.4 mg maintenance dose, your doctor may keep you at 1.7 mg.

Clinical Weight Loss Results

Wegovy's efficacy was demonstrated in the STEP clinical trial program, one of the largest obesity treatment trial programs ever conducted.

STEP 1: Adults Without Diabetes

In 1,961 adults with obesity or overweight, participants on Wegovy lost an average of 14.9 percent of their body weight over 68 weeks, compared to 2.4 percent in the placebo group. Approximately one-third of participants lost 20 percent or more of their body weight.

STEP 2: Adults With Type 2 Diabetes

In 1,210 adults with type 2 diabetes and overweight or obesity, average weight loss was 9.6 percent with Wegovy versus 3.4 percent with placebo over 68 weeks. Weight loss tends to be somewhat lower in patients with type 2 diabetes due to the metabolic complexity of the condition.

STEP 3: With Intensive Behavioral Therapy

When combined with intensive behavioral therapy (including a low-calorie diet for the first 8 weeks), participants lost an average of 16 percent of their body weight, suggesting that lifestyle interventions can enhance the medication's effects.

SELECT Trial: Cardiovascular Outcomes

The landmark SELECT trial enrolled over 17,000 adults with obesity or overweight and established cardiovascular disease but without diabetes. Wegovy reduced the risk of major adverse cardiovascular events by 20 percent. This trial changed the perception of obesity treatment from a cosmetic concern to a serious medical intervention with life-saving benefits.

The SELECT trial demonstrated that treating obesity with Wegovy saves lives. A 20 percent reduction in heart attacks, strokes, and cardiovascular death is comparable to the benefit seen with widely used statin medications.

Side Effects of Wegovy

Wegovy shares the same side effect profile as other semaglutide products. The most common side effects are gastrointestinal and are usually most pronounced during dose escalation.

• Nausea (reported by about 44% of patients in trials, though often mild and transient)
• Diarrhea (approximately 30%)
• Vomiting (approximately 24%)
• Constipation (approximately 24%)
• Abdominal pain
• Headache
• Fatigue
• Injection site reactions

Approximately 7 percent of participants in clinical trials discontinued Wegovy due to side effects, compared to about 3 percent in the placebo group. Serious but rare side effects include pancreatitis, gallbladder disease, kidney injury, and suicidal ideation (monitored but not confirmed as causally related).

Insurance Coverage and Cost

Insurance coverage for Wegovy remains inconsistent. Because it is classified as an anti-obesity medication rather than a diabetes drug, many plans do not cover it, or they impose significant restrictions.

• Commercial insurance: Coverage varies widely. Some plans cover Wegovy with prior authorization; others exclude all anti-obesity medications.
• Medicare: Historically, Medicare has not covered weight loss drugs. Legislative efforts to change this are ongoing.
• Employer-sponsored plans: An increasing number of employers are adding obesity medication coverage, especially after the SELECT cardiovascular data.
• Manufacturer savings: Novo Nordisk offers savings cards for eligible commercially insured patients, potentially reducing copays significantly.
• Cash pay: Without insurance, Wegovy costs approximately $1,300 to $1,400 per month at retail pharmacies.

Who Is Wegovy For?

Wegovy may be appropriate for you if you meet the following criteria:

• You are an adult with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition.
• You have been unable to achieve or maintain meaningful weight loss through diet and exercise alone.
• You do not have a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome.
• You are not pregnant, breastfeeding, or planning to become pregnant within the next two months.
• You are willing to commit to the weekly injection schedule and ongoing follow-up with your healthcare provider.

Key Takeaways

Wegovy represents a genuine breakthrough in obesity treatment. With average weight loss of nearly 15 percent of body weight and proven cardiovascular benefits, it offers clinically meaningful results for patients who have struggled with excess weight. While cost and insurance coverage remain barriers for many, the growing body of evidence supporting GLP-1 therapy for obesity is driving policy changes. Talk to your healthcare provider to determine whether Wegovy is the right option for your weight management goals.

Sources

• Wegovy (semaglutide) Prescribing Information. Novo Nordisk.
• Wilding et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM.